ClinicalTrials.gov
public full text
Public Domain
Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
The aim of this study is to test the effect of a new drug on the composition of the urine in kidney stone patients. This new drug (Jardiance®, substance: empagliflozin) is currently approved in Switzerland for the treatment of patients with diabetes. Data from previous studies with and without diabetes suggest that it may have a beneficial effect on the composition of the urine and thereby reduce the risk of developing kidney stones.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones#1032043
- Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients#1007507
- Normal Reference Ranges for Urinary Metabolites and Supersaturation Indices in Pediatric Populations#897426
- Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2#1282942
- Differences in Urine NGAL Levels in Patients Undergoing RIRS With or Without Ureteral Access Sheath#916426
Record · ID 1246410
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive